Reference: GILA/ID/NRC-033/CDMO
Board seat: Independent Director, Non-Executive
Primary board location: Ahmedabad with development and manufacturing campuses
Meeting model: Five board, five NRC and two scientific-talent reviews
Mandate type: NRC Chair & Board Succession Expert
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A listed contract development and manufacturing organisation producing complex small-molecule ingredients and finished doses for innovator clients, with regulated-market inspections.
Revenue is ₹4,500–6,000 crore. The chief scientific officer and quality head both become retirement-eligible within eighteen months while the company adds high-potency capacity.
The board problem and strategic reason for appointment
The NRC must protect independent quality leadership and succession in scarce scientific roles. Replacing one star scientist with another is not a system; the board needs role architecture, deputies, retention and technical-career paths.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
NRC Chair; member of Quality/Risk; oversees succession and reward for KMPs/control functions without directing laboratory work.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Establish emergency and planned succession for scientific, quality and site-leadership roles; test whether quality reporting and reward remain independent of batch-release pressure; create technical-career and retention architecture below executive level; review key-person clauses, client confidence and knowledge transfer for critical programmes
- Turn succession from an annual name-list exercise into a board-owned system covering CEO emergency cover, two-ready-now depth, pivotal roles, development evidence and decision rights.
- Redesign executive and board evaluation so reward, risk, culture and long-horizon value are connected; document how the NRC handles underperformance, key-person dependency and promoter influence.
Decision profile sought
Essential evidence
- CHRO, pharma CEO, quality leader or NRC Chair with scientific-talent succession; regulated manufacturing understanding; control-function remuneration judgement
Differentiators
- Global CDMO organisation design or technical fellowship systems; experience replacing a founder-scientist or long-tenured quality leader
GILA will assess first-hand succession decisions, remuneration judgement, organisation design literacy and the independence to surface uncomfortable evidence about powerful leaders. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Recruiter, client, competitor or scientific-advisory ties; coaching of internal candidates; consultancy that designed current reward architecture.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects credible leadership continuity, a decision-grade talent dashboard and remuneration outcomes the board can defend to shareholders and employees. For this particular seat, the evidence will be:
- Named and assessed successors for critical roles; quality-leader reward has independent safeguards; technical attrition, knowledge concentration and client continuity tracked
Commitment, protection and economics
- Expected load: 20–24 days annually with campus immersion.
- Terms: Five-year term; chair fee; product/regulatory and D&O protection.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.